Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBW-3220 Bioavailability and Food Effect Study in Healthy Participants
NCT07799597Phase 1Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Sep 2026
- Primary completion
- Jul 2028
01
Overview
Phase 1, randomised, open-label trial of HBW-3220 (3 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 72 hours and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HBW-3220
Beyond the preview
Go deeper on NCT07799597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799597.